These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1200 related articles for article (PubMed ID: 25948774)
21. Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis. Wang J; Li G; Wang Y; Tang S; Sun X; Feng X; Li Y; Bao G; Li P; Mao X; Wang M; Liu P Oncotarget; 2015 Dec; 6(42):44579-92. PubMed ID: 26625311 [TBL] [Abstract][Full Text] [Related]
22. Brucine, an indole alkaloid from Strychnos nux-vomica attenuates VEGF-induced angiogenesis via inhibiting VEGFR2 signaling pathway in vitro and in vivo. Saraswati S; Agrawal SS Cancer Lett; 2013 May; 332(1):83-93. PubMed ID: 23348691 [TBL] [Abstract][Full Text] [Related]
23. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853 [TBL] [Abstract][Full Text] [Related]
24. Cell-permeable iron inhibits vascular endothelial growth factor receptor-2 signaling and tumor angiogenesis. Kir D; Saluja M; Modi S; Venkatachalam A; Schnettler E; Roy S; Ramakrishnan S Oncotarget; 2016 Oct; 7(40):65348-65363. PubMed ID: 27589831 [TBL] [Abstract][Full Text] [Related]
25. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629 [TBL] [Abstract][Full Text] [Related]
26. HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma. Lai XM; Liu SY; Tsai YT; Sun GH; Chang SY; Huang SM; Cha TL Oncotarget; 2017 Jul; 8(30):49713-49724. PubMed ID: 28572533 [TBL] [Abstract][Full Text] [Related]
27. Aromatic Hydrocarbon Receptor Suppresses Prostate Cancer Bone Metastasis Cells-Induced Vasculogenesis of Endothelial Progenitor Cells under Hypoxia. Huang S; Guo Y; Jacobi A; Li Z; Huang S; He J; Liu X; Tang Y Cell Physiol Biochem; 2016; 39(2):709-20. PubMed ID: 27448695 [TBL] [Abstract][Full Text] [Related]
28. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha. Forooghian F; Das B Am J Ophthalmol; 2007 Nov; 144(5):761-8. PubMed ID: 17869204 [TBL] [Abstract][Full Text] [Related]
30. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects. Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666 [TBL] [Abstract][Full Text] [Related]
31. SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells. Young E; Miele L; Tucker KB; Huang M; Wells J; Gu JW Cancer Biol Ther; 2010 Oct; 10(7):703-11. PubMed ID: 20686367 [TBL] [Abstract][Full Text] [Related]
32. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF. Knowles HJ; Athanasou NA J Pathol; 2008 May; 215(1):56-66. PubMed ID: 18283716 [TBL] [Abstract][Full Text] [Related]
33. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops. Adamcic U; Skowronski K; Peters C; Morrison J; Coomber BL Neoplasia; 2012 Jul; 14(7):612-23. PubMed ID: 22904678 [TBL] [Abstract][Full Text] [Related]
34. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522 [TBL] [Abstract][Full Text] [Related]
35. Stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid/HIF-1α/VEGF signalling in MCF-7 breast cancer cells. Ciccone V; Terzuoli E; Donnini S; Giachetti A; Morbidelli L; Ziche M J Exp Clin Cancer Res; 2018 Dec; 37(1):311. PubMed ID: 30541574 [TBL] [Abstract][Full Text] [Related]
36. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514 [TBL] [Abstract][Full Text] [Related]
37. Direct effect of bevacizumab on glioblastoma cell lines in vitro. Simon T; Coquerel B; Petit A; Kassim Y; Demange E; Le Cerf D; Perrot V; Vannier JP Neuromolecular Med; 2014 Dec; 16(4):752-71. PubMed ID: 25113866 [TBL] [Abstract][Full Text] [Related]
39. Suppression of VEGF expression through interruption of the HIF‑1α and Akt signaling cascade modulates the anti‑angiogenic activity of DAPK in ovarian carcinoma cells. Park ST; Kim BR; Park SH; Lee JH; Lee EJ; Lee SH; Rho SB Oncol Rep; 2014 Feb; 31(2):1021-9. PubMed ID: 24337450 [TBL] [Abstract][Full Text] [Related]
40. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]